BY M.P. HILL, C.J. HILLE AND J.M. BROTCHIE

Recent studies demonstrate that stimulation of d-opioid receptors can produce potent antiparkinsonian effects in both rat and primate models of Parkinson's disease.
(44 Kb) (349 Kb)

Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS

BY ARMIN BLESCH

Gene therapy will clearly play an important role in the delivery of molecules to neuronal targets in the CNS. Further improvements in vector design and production, such as exogenous control over gene expression or inducible inactivation of vectors or grafted cells, are actively being investigated.
(86 Kb) (173 Kb)

Neuropathological, Biochemical and Genetic Alterations in AD

Given the central and probably early role that abnormal processing of APP plays in the genesis of Alzheimer's disease, most current efforts are directed at either modulating A peptide production or inhibiting its ability to aggregate into fibrils and cause neurotoxicity.
(49 Kb) (224 Kb)

Immunotherapeutic Applications of CpG-Containing Oligodeoxynucleotides

BY DENNIS M. KLINMAN, KEN ISHII, MAYDA GURSEL, IHSAN GURSEL, SAOKO TAKESHITA AND FUMIHIKO TAKESHITA

The use of CpG ODN as antiallergens, anticancer agents and immunoprotective agents has attracted considerable interest.
(45 Kb) (351 Kb)

NME Digest

Fifty-seven New Molecular Entities are reported this month: A-204176, A-285222, AR-C68164AA, AR-C68475AA, AR-C69457, AR-C89855AA, AU-461, BA-129, Bay-19-8004, C220, CBX-10913, Cf-1368, CGH-2466, CT-5219, DB-368, DY-9804, EMD-76334 AM, enfumafungin, ER-38930, ER-41666, eryloside F, Fiduxosin, GI-270384X, GT-160-246, GW-273629, GW-274150, HI-368, ISIS-17470, IVL-745, JJ319, JMV-1639, JMV-1645, KUL-7211, L-377202, L-771688/SNAP-6383), LU-302146, LU-420627, NCX-1000, nocardione A, nocardione B, NPPC, NTP-15-5, NTPC, OX-40­maytansine, PA-344, PA-457, recombinant cholera toxin subunit B, RPR-115781, SB-203207, SB-203208, SB-219383, SD-3651, SK-896, SL-650472, T-0162, VUF-5574 and WLSA-5..
(60 Kb) (159 Kb)

New Product Intros

Ganirelix acetate; insulin glargine (rDNA origin); lafutidine; peginterferon; somatropin (rDNA origin) (new formulation); and testosterone gel 1%.
(8 Kb) (56 Kb)

Licensing Line

Information on product and technology licensing opportunities with various private and public entities: U.S. National Institutes of Health
(13 Kb) (64 Kb)

Molecule of the Month

HCT-1026.
(6 Kb) (50 Kb)

MEETING REPORTS

Basic and Patient-Oriented Research in Organ Transplantation

BY R. MÁÑEZ

Highlights of TRANSPLANT 2000, held May 13­17, 2000, in Chicago.
(13 Kb) (53 Kb)

ASH News on Hypertension

BY ALEIX CASES

Highlights of the 15th Scientific Meeting of the American Society of Hypertension, held May 16­20, 2000, in New York City.
(25 Kb) (81 Kb)